Fangxin Hong

7PUBLICATIONS
67CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMedia industry studies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Feb 28, 2023
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B.

Amy S Clark, Fangxin Hong, Richard S Finn

|Jul 05, 2022
Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials.

Sarah C Rutherford, Jun Yin, Levi Pederson

|Jul 12, 2021
Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Non-Small-Cell Lung Cancer.

Mizuki Nishino, Fangxin Hong, Biagio Ricciuti

|Feb 08, 2021
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412.

Grzegorz S Nowakowski, Fangxin Hong, David W Scott

|Oct 07, 2020
Threats of Bots and Other Bad Actors to Data Quality Following Research Participant Recruitment Through Social Media: Cross-Sectional Questionnaire.

Rachel Pozzar, Marilyn J Hammer, Meghan Underhill-Blazey

Pageof 2